The Clorox Company $CLX Shares Bought by Ieq Capital LLC

Key Points

• Ieq Capital LLC significantly increased its stake in The Clorox Company by 236.4%, acquiring an additional 13,889 shares, bringing its total holdings to 19,763 shares valued at approximately $2.91 million.
• Multiple hedge funds, including HSBC and KBC Group, also expanded their positions in Clorox, indicating a strong interest from institutional investors, which now own 78.53% of the company's stock.
• Clorox reported earnings of $2.87 per share, exceeding estimates, and declared a quarterly dividend increase to $1.24, reflecting a commitment to returning value to shareholders.

Ieq Capital LLC lifted its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 236.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,763 shares of the company's stock after acquiring an additional 13,889 shares during the quarter. Ieq Capital LLC's holdings in Clorox were worth $2,910,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Hsbc Holdings PLC lifted its position in shares of Clorox by 118.8% during the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company's stock valued at $159,699,000 after buying an additional 589,544 shares in the last quarter. KBC Group NV lifted its position in shares of Clorox by 688.7% during the 1st quarter. KBC Group NV now owns 587,679 shares of the company's stock valued at $86,535,000 after buying an additional 513,171 shares in the last quarter. Man Group plc lifted its position in shares of Clorox by 154.6% during the 4th quarter. Man Group plc now owns 570,503 shares of the company's stock valued at $92,655,000 after buying an additional 346,449 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Clorox by 11,108.0% during the 1st quarter. GAMMA Investing LLC now owns 349,130 shares of the company's stock valued at $51,409,000 after buying an additional 346,015 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its position in shares of Clorox by 28.7% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,421,909 shares of the company's stock valued at $230,932,000 after buying an additional 316,688 shares in the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CLX shares. Citigroup reaffirmed a "neutral" rating and issued a $135.00 price target (down from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. UBS Group decreased their price target on shares of Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. Barclays decreased their price target on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating on the stock in a research note on Tuesday, July 15th. Morgan Stanley decreased their price target on shares of Clorox from $150.00 to $137.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. Finally, Wells Fargo & Company lifted their target price on shares of Clorox from $135.00 to $138.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Reduce" and an average price target of $143.36.

Clorox Trading Up 0.9%

Shares of NYSE CLX traded up $1.15 during trading on Thursday, hitting $124.06. 1,555,055 shares of the company were exchanged, compared to its average volume of 1,655,820. The Clorox Company has a 12-month low of $116.53 and a 12-month high of $171.37. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The company has a fifty day moving average price of $123.87 and a 200-day moving average price of $133.78. The firm has a market capitalization of $15.17 billion, a PE ratio of 19.03, a P/E/G ratio of 0.94 and a beta of 0.52.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter in the previous year, the firm earned $1.82 EPS. The company's quarterly revenue was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, equities research analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Clorox Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Investors of record on Wednesday, August 13th were issued a $1.24 dividend. This is a boost from Clorox's previous quarterly dividend of $1.22. This represents a $4.96 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date was Wednesday, August 13th. Clorox's payout ratio is currently 76.07%.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.